Mahesh Swaminathan

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, Hagop M. Kantarjian, Naval Daver et al. · Blood · 2017 · 73 citations

Medicine, Oncology, Pharmacology +15

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome

Mahesh Swaminathan, Hagop M. Kantarjian, Mark J. Levis et al. · Haematologica · 2021 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Courtney D. DiNardo, Wei‐Ying Jen, Koichi Takahashi et al. · Leukemia · 2025 · 35 citations · Full text

Medicine, Hematology, Oncology +16

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

Christophe Willekens, Alexandre Bazinet, Samy Chraïbi et al. · Blood Cancer Journal · 2025 · 27 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Prithviraj Bose, Mahesh Swaminathan, Naveen Pemmaraju et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 24 citations · Full text

Medicine, Hematology, Pharmacology +10